10,911 Shares in Boston Scientific Co. (NYSE:BSX) Purchased by Portfolio Design Labs LLC

Portfolio Design Labs LLC purchased a new position in shares of Boston Scientific Co. (NYSE:BSX) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 10,911 shares of the medical equipment provider’s stock, valued at approximately $975,000.

A number of other large investors have also recently made changes to their positions in BSX. Thurston Springer Miller Herd & Titak Inc. boosted its stake in shares of Boston Scientific by 32.4% during the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 3,786 shares of the medical equipment provider’s stock worth $317,000 after purchasing an additional 927 shares during the period. ORG Wealth Partners LLC purchased a new position in shares of Boston Scientific during the 3rd quarter worth about $89,000. Grove Bank & Trust boosted its stake in shares of Boston Scientific by 12.9% during the 3rd quarter. Grove Bank & Trust now owns 2,801 shares of the medical equipment provider’s stock worth $235,000 after purchasing an additional 320 shares during the period. Creative Planning boosted its position in Boston Scientific by 7.7% in the 3rd quarter. Creative Planning now owns 204,208 shares of the medical equipment provider’s stock valued at $17,113,000 after buying an additional 14,663 shares during the period. Finally, Boomfish Wealth Group LLC purchased a new stake in Boston Scientific in the 3rd quarter valued at about $281,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on BSX shares. Piper Sandler boosted their price objective on shares of Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Truist Financial boosted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a research report on Thursday, February 6th. Mizuho boosted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Finally, TD Cowen boosted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $107.39.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the transaction, the director now owns 39,398 shares in the company, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP John Bradley Sorenson sold 6,528 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $104.97, for a total transaction of $685,244.16. Following the completion of the sale, the executive vice president now owns 26,449 shares in the company, valued at $2,776,351.53. The trade was a 19.80 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 53,830 shares of company stock worth $5,149,969. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Trading Down 0.1 %

NYSE BSX opened at $106.03 on Wednesday. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The firm has a market cap of $156.26 billion, a PE ratio of 84.82, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. The company has a 50 day moving average price of $95.19 and a 200 day moving average price of $87.50. Boston Scientific Co. has a 52 week low of $64.54 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. As a group, sell-side analysts forecast that Boston Scientific Co. will post 2.83 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.